In order to leverage its technical potential, Lonza Ltd has decided to strengthen the existing Lonza Engineeing organization. Klaus Kalbermatter will take over this new position. After the successful integraton of Lonza Braine SA, Stéphane Mischler will return to the Visp site. As of 1 July, he will stepwise take back over the site management from Klaus Kalbermatter.
As of 10 August 2009, Klaus Kalbermatter, presently site manager in Visp and Head of Life Science Ingredients Services, will take charge of the expansion of the Lonza Engi-neering organization. In this function, he will continue to report to Lukas Utiger, Head of the Life Science Ingredients division.
Klaus Kalbermatter has been the Head of the Life Science Ingredients Services for the last five years and additionally the site manager of Visp for the last three years, contributing significantly to the development of the Visp site. We owe him many thanks for his extraordinary commitment for Lonza’s interests and for his dedication. We are convinced that his broad experience will sustainably support and facilitate the build-out of a global Lonza Engineering organization.
Stéphane Mischler, who had already successfully managed the Visp site from 1997 to 2006, will take over the position as Site Manager of the Visp site and Head of Life Science Ingredients Services. We would like to thank Stéphane Mischler for his hitherto contribution and welcome him back in the site. We look forward to his continuing valu-able support. Stéphane Mischler will also report to Lukas Utiger.
We thank Stéphane Mischler for his extraordinary commitment and the successful inte-gration of Lonza Braine SA in Belgium and wish him a lot of success for his future tasks.
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, en-dotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2008, Lonza had sales of CHF 2.937 billion. Further information can be found at www.lonza.com.
For further information:
Tel +41 27 948 5575
Fax +41 27 947 5575